MONOCLONAL ANTIBODY-M3 USED IN TISSUE POLYPEPTIDE-SPECIFIC ANTIGEN-ASSAY FOR THE QUANTIFICATION OF TISSUE POLYPEPTIDE ANTIGEN RECOGNIZES KERATIN-18

被引:52
作者
BONFRER, JMG
GROENEVELD, EM
KORSE, CM
VANDALEN, A
OOMEN, LCJM
IVANYI, D
机构
[1] NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT TUMOR BIOL,1066 CX AMSTERDAM,NETHERLANDS
[2] NETHERLANDS CANC INST,ANTONI VAN LEEUWENHOEK HUIS,DEPT BIOPHYS,1066 CX AMSTERDAM,NETHERLANDS
[3] GROENE HART HOSP,DEPT NUCL MED,GOUDA,NETHERLANDS
关键词
MONOCLONAL ANTIBODIES; ASSAY; CYTOKERATINS; CELL LINES;
D O I
10.1159/000217894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, a new 'specific tissue polypeptide antigen (TPA)' test was introduced and designated tissue polypeptide-specific antigen (TPS); it is based on the monoclonal antibody (MAb) anti-TPS, M3. We have tested the specificity of this antibody by immunocyto- and immunohistochemistry, gel electrophoresis and immunoblotting. MAb M3 bound to intermediate filaments of epithelial cells and revealed a staining pattern identical to cytokeratin (CK) 18-specific MAb (DE-K18) on tissue sections of various human tissues. On immunoblots of proteins extracted from various epithelial cell lines, M3 reacted with a 45-kD protein corresponding to CK18, and on immunoblots of proteins isolated from MCF-7 culture fluid M3 stained three bands, 45, 33 and 29 kD. The same bands were stained with CK18-specific MAb, indicating that they represent CK18 and its degradation products. TPA, used as a tumor marker in clinical diagnoses and follow-up, was shown to be a degradation product of CK 8, 18 and 19. In contrast to TPA, MAb M3 did not stain CK8 and CK19 present on immunoblots.
引用
收藏
页码:210 / 222
页数:13
相关论文
共 48 条
  • [1] DIFFERENTIAL EXPRESSION OF KERATIN-19 IN NORMAL HUMAN EPITHELIAL TISSUES REVEALED BY MONOSPECIFIC MONOCLONAL-ANTIBODIES
    BARTEK, J
    BARTKOVA, J
    TAYLORPAPADIMITRIOU, J
    REJTHAR, A
    KOVARIK, J
    LUKAS, Z
    VOJTESEK, B
    [J]. HISTOCHEMICAL JOURNAL, 1986, 18 (10): : 565 - 575
  • [2] ANTIGENICITY OF POOLED HUMAN MALIGNANT AND NORMAL TISSUES BY CYTO-IMMUNOLOGICAL TECHNIQUE - PRESENCE OF AN INSOLUBLE, HEAT-LABILE TUMOR ANTIGEN
    BJORKLUND, B
    BJORKLUND, V
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1957, 10 (03): : 153 - 184
  • [3] BJORKLUND B, 1992, TUMORDIAGN THER, V13, P43
  • [4] BROERS JLV, 1988, CANCER RES, V48, P3221
  • [5] CYTOKERATIN EXPRESSION IN SMOOTH-MUSCLE AND SMOOTH-MUSCLE TUMORS
    BROWN, DC
    THEAKER, JM
    BANKS, PM
    GATTER, KC
    MASON, DY
    [J]. HISTOPATHOLOGY, 1987, 11 (05) : 477 - 486
  • [6] CELLULAR AND HUMORAL IMMUNE RESPONSES TO HUMAN URINARY BLADDER CARCINOMAS
    BUBENIK, J
    PERLMANN, P
    HELMSTEIN, K
    MOBERGER, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1970, 5 (03) : 310 - +
  • [7] CHAN R, 1985, DEV ONCOL, V35, P165
  • [8] CHAN R, 1986, CANCER RES, V46, P1
  • [9] RAT ANTIKERATIN MONOCLONAL-ANTIBODIES ARE SPECIFIC FOR STRATIFIED SQUAMOUS EPITHELIA
    CHIN, NW
    LAI, BT
    LANKS, KW
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1988, 89 (03) : 315 - 320
  • [10] COOPER D, 1985, LAB INVEST, V52, P243